Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
D.R. Horton (NYSE: DHI), the largest U.S. homebuilder by volume, has taken investors on a roller-coaster ride over the last ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...
We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...
Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for ...
Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings report. The company traded as high as $26.69 and last traded at $26.62.
Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement saying his office and 37 other states, including Puerto Rico, had settled ...
specifically the migraine headache treatment Nurtec ODT, according to the Florida Office of the Attorney General. In the settlement agreement from the U.S. Department of Justice, it states health ...
Meanwhile, two oral CGRP inhibitors – AbbVie’s Ubrelvy and BioHaven’s Nurtec – have been launched for the on-demand treatment of acute migraine attacks. These don’t compete with Aimovig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results